U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07833839) titled 'ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma' on Sept. 16.
Brief Summary: This is a randomized, double-blind, controlled, multicenter Phase III study evaluating the efficacy, safety, pharmacokinetics, and immunogenicity of ZG005 combined with the EP regimen (etoposide plus cisplatin) in participants with advanced NEC who are naive to systemic therapy.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Neuroendocrine Carcinomas (NEC)
Intervention:
DRUG: ZG005 for Injection
Intravenous infusion
DRUG: Etoposide Injection
Intravenou...